Alagille Syndrome

Also known as: Alagille Syndrome (ALGS) / Arteriohepatic dysplasia (disorder)

Drug	Drug Name	Drug Description
DB16226	Maralixibat	An ileal bile acid transporter inhibitor indicated to treat cholestatic pruritus in patients with Alagille syndrome.
DB16261	Odevixibat	An ileal sodium/bile acid cotransporter inhibitor indicated in the treatment of pruritus in patients with progressive familial intrahepatic cholestasis.

Drug	Drug Name	Target	Type
DB16226	Maralixibat	Ileal sodium/bile acid cotransporter	target
DB16226	Maralixibat	Solute carrier organic anion transporter family member 2B1	transporter
DB16226	Maralixibat	Cytochrome P450 3A4	enzyme
DB16226	Maralixibat	Hepatic sodium/bile acid cotransporter	target
DB16261	Odevixibat	Ileal sodium/bile acid cotransporter	target
DB16261	Odevixibat	ATP-dependent translocase ABCB1	transporter

Drug	Drug Name	Phase	Status	Count
DB13749	Magnesium gluconate	Not Available	Completed	1
DB00653	Magnesium sulfate	Not Available	Completed	1
DB16226	Maralixibat	Not Available	Approved for Marketing	1
DB16226	Maralixibat	Not Available	Recruiting	1
DB01432	Cholestyramine	1	Completed	1
DB16261	Odevixibat	1	Completed	2
DB16226	Maralixibat	2	Active Not Recruiting	1
DB16226	Maralixibat	2	Completed	5
DB16226	Maralixibat	3	Active Not Recruiting	1
DB16261	Odevixibat	3	Completed	1
DB16261	Odevixibat	3	Recruiting	1
DB01076	Atorvastatin	4	Recruiting	1